Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Filters applied. Clear all
. 2017 Jul 7;12(7):e0176858.
doi: 10.1371/journal.pone.0176858. eCollection 2017.

Effectiveness of Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Virus in Clinical Practice: A Population-Based Observational Study

Affiliations
Free PMC article

Effectiveness of Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Virus in Clinical Practice: A Population-Based Observational Study

Maya Leventer-Roberts et al. PLoS One. .
Free PMC article

Abstract

Background: Direct acting antivirals for hepatitis C virus have shown dramatic results in clinical trials. However, their effectiveness has yet to be demonstrated within observational cohorts which lack exclusion criteria found in randomized control trials.

Aim: To determine the effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir in achieving sustained virological response.

Methods: Retrospective observational cohort study of all Clalit Health Services members with hepatitis C virus genotype 1 who were dispensed dasabuvir/ombitasvir/paritaprevir/ritonavir from January 1, 2015 to-November 31, 2015.

Results: There were 564 participants during the study period. The average age was 61.9 years, 52.0% were male, and 61.5% were born Eastern/Central Europe or Central Asia. The prevalence of diabetes was 31.7% and 70.3% were overweight/obese. Cirrhosis was present in 41.0% of participants, of whom 52.8% had stage 4 fibrosis. Of the cohort, 416 (74.8%) had follow-up viral load testing at 10 or more weeks after the end of treatment. We report a sustained virological response of 98.8% among those tested.

Conclusions: Treatment with dasabuvir/ombitasvir/paritaprevir/ritonavir demonstrated a near universal effectiveness in achieving a sustained virological response among HCV patients in a large cohort.

Conflict of interest statement

Competing Interests: Dr. Braun reports receiving consulting fees from Abbvie, MSD, and Jansen; educational travel grants from Gilead and Novartis; and personal fees from Roche and BMS. All other authors have no conflicts of interest to disclose. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Results of last viral load among participants not assessed for SVR at 10 or more weeks after the end of treatment.
Abbreviations: SVR, sustained virological response.

Similar articles

See all similar articles

Cited by 1 article

References

    1. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(2):359–365. doi: 10.1053/j.gastro.2014.04.045 - DOI - PubMed
    1. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin. N Engl J Med. 2014;370(17):1594–1603. doi: 10.1056/NEJMoa1315722 - DOI - PubMed
    1. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983–1992. doi: 10.1056/NEJMoa1402338 - DOI - PubMed
    1. Gutierrez JA, Lawitz EJ, Poordad F. Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. J Viral Hepat. 2015;22(11):861–870. doi: 10.1111/jvh.12422 - DOI - PubMed
    1. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. N Engl J Med. 2014;370(21):1973–82. doi: 10.1056/NEJMoa1402869 - DOI - PubMed

MeSH terms

Grant support

The authors received no specific funding for this work.
Feedback